Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
收盘时
US$0.2183
−US$0.0114 · -4.96%
盘中时间采用ET。市场数据可能有所延迟。
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
日内区间
当前US$0.2183
52周区间
当前US$0.2183
盘中时间采用ET。市场数据可能有所延迟。
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
日内区间
当前US$0.2183
52周区间
当前US$0.2183
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 4.02亿 USD | 4.59亿 USD | 4.47亿 USD | 4.48亿 USD | 4.3亿 USD |
| 销货成本 | 2.9亿 USD | 3.12亿 USD | 3.04亿 USD | 2.94亿 USD | 2.7亿 USD |
| 毛利 | 1.11亿 USD | 1.47亿 USD | 1.43亿 USD | 1.54亿 USD | 1.6亿 USD |
| 研究与开发 | 3775.3万 USD | 4794.2万 USD | 4973.2万 USD | 5712.9万 USD | 5775.2万 USD |
| 销售、一般及管理费用 | 8397.1万 USD | 9118.6万 USD | 9268.5万 USD | 9444.9万 USD | 9405.5万 USD |
| 营业费用 | 1.38亿 USD | 1.39亿 USD | 1.42亿 USD | 1.52亿 USD | 1.52亿 USD |
| 利息收入 | — | 119.2万 USD | — | — | — |
| 利息支出 | 3531万 USD | 1295.4万 USD | 1162.4万 USD | 1063.2万 USD | 812.9万 USD |
| 折旧和摊销 | 794.2万 USD | 615万 USD | 590.5万 USD | 452.7万 USD | 551.3万 USD |
| 营业利润 | −2644.2万 USD | 783.9万 USD | 50.4万 USD | 238.2万 USD | 814.8万 USD |
| 净利润 | −4919.4万 USD | −159.1万 USD | −1554.5万 USD | −928万 USD | −534.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$2.00
上涨空间 816.17%价格历史记录不可用
最高:US$2.00平均的:US$2.00最低:US$2.00报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI82.12万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Fidelity Enhanced Small Cap ETFFESM33万0.01%64.1亿 USD0.28%US$45.24-0.48%
Vanguard Extended Market ETFVXF31.3万0.00%954亿 USD0.05%US$233.52-0.63%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM2.84万0.00%6.94亿 USD0.89%US$57.21-0.67%
Invesco RAFI US 1500 Small-Mid ETFPRFZ2.65万0.00%26.7亿 USD0.36%US$52.92-0.45%
Vanguard Morningstar Total Stock Market ETFVTI
Fidelity Enhanced Small Cap ETFFESM
Vanguard Extended Market ETFVXF
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM
Invesco RAFI US 1500 Small-Mid ETFPRFZAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。